EVAX News and Press, Evaxion Biotech A/S

Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focus In future, Evaxion’s proprietary AI-Immunology™ platform will enable the discovery and development of drug candidates targeting cancer, infectious and autoimmune diseases, leveraging its u...

COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech Showcase conference taking place from January 12-14, 2026, in San Francisco,...

MSD declines to exercise option for EVX-B2 development Evaxion is now able to out-license EVX-B2 to another partner Evaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studies There is no impact on Evaxion’s cash runway ...

Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens EVX-04 induces targeted immune responses and prevents tumor growth in preclinical models EVX-04 is an ...

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of establi...

COPENHAGEN, Denmark, November 12, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its financial calendar for 2026 as summarized below: March 5, 2026 : Business update...

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01’s already strong data package...

2025-11-06 19:56:08 ET Evaxion A/S (EVAX) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Birgitte Rono - Interim CEO & Chief Scientific Officer Thomas Schmidt - Chief Financial Officer ... Read the full article on Seeking Alpha ...

2025-11-06 07:37:29 ET More on Evaxion Biotech ADS Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma - Slideshow Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript ...

COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2025 financial results. Business highlights ...